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(catabolic stimulation), prednisolone + OSM + TNF-α, or IGF-I [100 nM]
(anabolic stimulation). The conditioned medium from days 7 and 14 were
measured and examined for biochemical markers of bone and cartilage
degradation/formation.
Results: The cartilage degradation increased ∼25-fold (day 7) and ∼20-fold
(day 14) when stimulated with the cytokines, OSM + TNF-α, compared
with the non-stimulated vehicles (P<0.001). Additional stimulation with
prednisolone inhibited the catabolic effects by OSM + TNF-α at both days
(P<0.01). The bone resorption also increased ∼5.5-fold (day 7) when
stimulated with OSM + TNF-α, compared with the vehicle (P<0.001). Again,
additional stimulation with prednisolone inhibited the catabolic effect on
bone resorption by OSM + TNF-α (P<0.05). No resorption was detected for
any treatments at day 14.
Prednisolone stimulation did not affect the cartilage formation. However,
IGF-I stimulation increased cartilage formation by ∼2.7-fold (day 14) com-
pared with the vehicle (P<0.001). OSM + TNF-α stimulation inhibited all
cartilage formation (P<0.001).
The bone formation was not affected by prednisolone stimulation at day 7.
However, at day 14, prednisolone decreased the bone formation by ∼8.9
fold compared with vehicle (P<0.001). IGF-I stimulation increased the bone
formation ∼2.5-fold (day 7) and ∼2.6-fold (day 14), compared with the
vehicles (P<0.001). OSM + TNF-α stimulation decreased bone formation
by ∼3.5-fold (day 7) compared with vehicle, and completely inhibited the
formation at day 14 (P<0.001).
Conclusions: Prednisolone inhibits cytokine-induced cartilage degradation
and bone resorption, indicating an anti-catabolic effect on chondrocytes
and osteoclasts. Cartilage formation is not affected by prednisolone, which
supports the literature suggesting that glucocorticoids protect cartilage.
However, bone formation decreased when stimulated with prednisolone,
suggesting that prednisolone catabolically affects the osteoblasts. This
overall indicates that prednisolone decreases bone turnover and protects
cartilage against degradation.
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HOW GOOD IS ALLOGRAFT CARTILAGE?
S. Kirk1, D. Ruta1, A. Meininger1, G. Filardo2, A. Hakimiyan1,
L. Rappoport1, B. Cole3,1, A. Kurz4, S. Chubinskaya1
1Rush Univ. Med. Ctr., Chicago, IL; 2Rizzoli Orthopaedic Inst., Bologna, Italy;
3Midwest Orthopaedics, Chicago, IL; 4Joint Restoration Fndn., Centennial, CO
Purpose: The purpose of this study was to evaluate the effect of pro-
inﬂammatory cytokines on the metabolism and survival of chondrocytes
obtained from osteochondral allografts (OA) as compared to fresh chondro-
cytes obtained from human organ donors.
Methods: Nine OA specimens (hemicondyle), previously refrigerated for
14-28 days, were collected at the time of surgery and six fresh hemi-
condyles were obtained from normal donors within 24 hours of death
through the Gift of Hope Organ and Tissue Donor Network. 4mm tissue
explants from OA and fresh cartilage were cultured in media containing
10% fetal bovine serum and divided into the following treatment groups:
1) culture control (serum only), 2) IL-1β (0.1 ng/ml), 3) IL-6 (3ng/ml), 4)
IL-1β (0.1 ng/ml) + IL-6 (3ng/ml), 5) IL-1β (10 ng/ml), 6) IL-1β (10 ng/ml)
+ IL-6 (3ng/ml). IL-6 soluble receptor (5ng/ml) was added to all cultures
containing IL-6. Doses of cytokines were determined based on synovial
ﬂuid levels in patients undergoing allograft transplantation. Treatment was
administered every other day. Tissue and media were collected on days 0,
2, 7, and 14. Cell viability (live/dead assay), apoptosis (Tunel assay), his-
tological appearance with Safranin O staining, proteoglycan (PG) synthesis
and content (normalized to wet weight) were used to analyze cartilage
survival and metabolism.
Results: At day zero, the viability of OA chondrocytes was 24% lower and
they contained 29% more apoptotic cells than fresh chondrocytes (p<0.05).
Treatment with cytokines did not further induce cell death or apoptosis
in OA cartilage. However, in fresh cartilage, treatment with high dose IL-1
(10ng/ml) alone or in combination with IL-6 showed a signiﬁcant decrease
in chondrocyte viability by day 14 (p<0.05 and p=0.05 correspondingly)
as well as a signiﬁcant increase in the number of apoptotic cells (p=0.05
and p<0.05) when compared to day 0 control. Fresh chondrocytes showed
2.5 times greater PG synthesis (p<0.05) and only half as much release of
PGs into the media (p<0.01) when compared to OA chondrocytes at day 0.
However, fresh chondrocytes were more sensitive to cytokine treatments:
by day 14 high dose IL-1 alone or combined with IL-6 inhibited PG
synthesis by more than 8-fold (p<0.02) vs 4-fold in OA cells (p<0.02) and
induced higher PG release, which resulted in higher Mankin score for fresh
cartilage (1.3 vs 3.0, p<0.04).
Conclusions: The viability and metabolism of OA cartilage is signiﬁcantly
lower than fresh cartilage; however, OA cartilage is more resistant to
cytokine treatment. The reduced metabolism and sensitivity of OA cartilage
might explain allograft survival in an acute inﬂammatory environment (at
least short-term) suggesting that OA cartilage may act more like a scaffold
rather than an active tissue. Further long-term studies are warranted in
order to understand the performance of OA cartilage.
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Purpose: It is increasingly recognised that the overproduction of mediators
such as Nitric Oxide (NO) in Osteoarthritic cartilage contributes to the
disease pathology partly by inducing chondrocyte apoptosis via the mi-
tochondrial pathway. Therefore, agents which protect against NO-induced
mitochondrial injury may have therapeutic potential in Osteoarthritis (OA).
We have previously shown that the human chondrocyte cell line C-20/A4
produces members of the Urocortin (Ucn) family of peptides in response
to pro-apoptotic insults and that exogenous administration of all of these
peptides protects chondrocytes from NO induced apoptosis with Ucn I
being the most potent. The purpose of this study was to elucidate poten-
tial mechanisms of action and signalling pathways through which these
peptides may exert their effects.
Methods: C-20/A4 cells were maintained in monolayer culture in a Dul-
becco’s MEM (DMEM) - based medium containing 10% foetal calf serum
(FCS) at 37 °C and 5% CO2. Prior to treatment, cells were transferred to
T25 tissue culture ﬂasks, allowed to reach approx. 80% conﬂuency and then
serum-starved for 24 hours in DMEM based medium containing 1% FCS and
then treated with 1mM SNAP (NO donor) for 6 hours. CRH receptor and
KATP channel subunit expression were analysed by RT-PCR. p42/44 MAPK
activation was studied by western blotting with antibodies speciﬁc for total
and phosphorylated p42/44. Apoptotic cell death was assessed by Annexin
V/PI binding and TUNEL assay with necrosis assessed by LDH release
Results: The addition of Ucn1 to SNAP treated C-20/A4 cells provides
protection against apoptosis which is abrogated by the addition of the
CRFR antagonist αhCRH suggesting the presence of CRH receptors on these
cells the expression of which was conﬁrmed by RT-PCR demonstrating
the expression of both corticotropin releasing factor receptors, CRFR1 and
CRFR2 mRNA, speciﬁcally the CRFR1α and CRFR2β splice variants. Further
RT-PCR studies demonstrate the expression of both the Kir and SUR
subunits of the mitochondrial ATP sensitive inwardly rectifying potassium
channel with western blotting studies indicating a Ucn mediated increase
in p42/44 MAPK activation, representing possible mechanisms for Ucn
mediated chondroprotection.
Conclusions: Studies with αhCRH and RT-PCR analysis for the expression of
CRFR receptors indicate the presence of two active forms of the CRF recep-
tors, CRFR1α and CRFR2β on C-20/A4 chondrocytes. The presence of these
receptors provides a putative cell surface binding site for Ucn family mem-
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bers to exert their cytoprotective effects which may be mediated through a
mechanism involving Kir 6.1-containing mitochondrial potassium channels,
which we have also shown to exist in this cell line. The observation that
these cells express both CRFR1 and CRFR2 is novel in that CRFR1 are largely
conﬁned to the central nervous system in humans, but would explain the
greater potency of Ucn I in chondroprotection as this peptide binds to both
CRFR1 and CRFR2 whilst Ucn II and Ucn III are selective CRFR2 ligands. The
demonstration that Ucn treatment results in p42/44 MAPK activation also
suggest the involvement of other cytoprotective mechanisms (e.g. cAMP
and PKA modulated responses) in Ucn mediated chondroprotection.
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A PEPTIDYL-GLUCOSAMINE DERIVATIVE AFFECTS IKKalpha KINASE
ACTIVITY IN HUMAN CHONDROCYTES
A. Scotto d’Abusco, L. Politi, P. Santini, D. Stoppoloni, R. Scandurra
Univ. of Roma, Roma, Italy
Purpose: NF-kappaB transcription factor regulates several cell signaling
pathways, such as differentiation and inﬂammation, which are both altered
in osteoarthritis. IKKalpha and IKKbeta are kinases involved in the activa-
tion of the NF-kappaB transcription factor. The aim of the present study
was to determine the effects of glucosamine, which is administered in the
treatment of osteoarthritis, and of its 2-(N-Acetyl)-L-phenylalanylamido-2-
deoxy-beta-D-glucose derivative (glucosamine-derivative) on IKK kinases
and, consequently, on NF-kappaB activation in human chondrocytes.
Methods: The human chondrosarcoma cell line HTB-94 and human pri-
mary chondrocytes were stimulated with TNFalpha after pre-treatment
with glucosamine or glucosamine-derivative. Gene mRNA expression level
was evaluated by Real Time-PCR. IkappaBalpha phosphorylation and p65
nuclear translocation were analyzed by Western blotting, IKKalpha nuclear
re-localization was investigated by immunocytochemistry and by Western
blotting. IKK kinase activity was studied by in vitro kinase assay, using IKK
complex immunoprecipitated by cells or using recombinant IKkalpha and
IKKbeta.
Results: After TNFalpha stimulation, the mRNA expression level of some
of the genes under NF-kappaB control, such as IL-6 and IL-8, increased,
while treatment with glucosamine and glucosamine-derivative reverted the
effect. We investigated the possibility that ﬂucosamine and its derivative
inhibit IKK kinase activity and found that glucosamine-derivative inhibits
the IKKalpha kinase activity, whereas glucosamine does not. Interestingly,
both molecules inhibit IKKalpha nuclear translocation.
Conclusions: Our results demonstrate that glucosamine and its peptidyl-
derivative can interfere with NF-kappaB signaling pathway by inhibit-
ing IKKalpha activity in human chondrocytes. However, the mechanism
of action of the two molecules is not completely overlapping. While
glucosamine-derivative can both speciﬁcally inhibit the IKKalpha kinase
activity and IKKalpha nuclear translocation, glucosamine only acts on
IKKalpha nuclear re-localization.
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A FULL-DEPTH CARTILAGE EXPLANTS CULTUREMODEL FOR
INVESTIGATING CHONDROCYTES HYPERTROPHIC IN OSTEOARTHRITIS
P. Chen, K. Andreassen, K. Henriksen, M.A. Karsdal, A.-C. Bay-Jensen
NordicbioSci. A/S, Herlev, Denmark
Purpose: Chondrocytes become hypertrophic, which leads to calciﬁ-
cation of cartilage matrix. This is a pathological event in the early
phase of osteoarthritis (OA). We are interested in three subpopulations:
pre-hypertrophic chondrocytes, hypertrophic chondrocytes and mature
hypertrophic chondrocytes, which are undergoing apoptosis. These three
subpopulations of hypertrophic chondrocytes play different role in patho-
genesis of OA. The aim of our work was to develop and validate an ex vivo
model, which includes the different subpopulations of chondrocytes, and in
which hypertrophic chondrocytes could be induced by adding appropriate
factors. This model was supposed to be used for examination of cartilage
changes related to morphological changes. Thus, aiding the understanding
of the role of hypertrophy chondrocytes in OA pathogenesis.
Methods: Full depth cartilage explants (from superﬁcial to calciﬁed carti-
lage) were isolated from bovine femoral condyle and cultured for 21 days
with different stimulators: 1) TNF-α [20ng/ml] + Oncostatin M [10ng/ml],
2) IGF-1 [100ng/ml], 3) bFGF [50ng/ml], and 4) BMP-2[100ng/ml]. Super-
natants were collected every two or three days. Safranin O/Fast Green
(SaFO) and Tuludine Blue (TuB) staining were used to distinguish the mor-
phology of the explants. Collagen type II turnover was measure by PIINP
(formation) and CIIMB (degradation) assay. As markers of hypertrophy
chondrocytes, expression of Indian hedgehog, type X collagen, ALP and
MMP-13 were evaluated using reverse transcription followed by real-time
polymerase chain reaction (PCR) at day 14.
Results: Alamarblue data showed that all explants were alive throughout
the 21 days. Both IGF-1 and bFGF groups had enlarged cells at day 7 and 14
(TuB and SaFO stainings). CIIMB and PIINP assay results suggested that both
IGF-1 and bFGF had signiﬁcant (p<0.05) collagen type II degradation and
formation at day 7, but not day 14 and 21. BMP-2 increased signiﬁcantly
expression of Ihh, COL X, ALP and MMP-13 at day 14 (p<0.0001) compared
with W/O. bFGF increased expression of Ihh and MMP-13 but not signiﬁ-
cantly, and the expression of COL X and ALP of bFGF stimulated group were
lower than W/O. The increased expression of hypertrophy chondrocytes
markers conﬁrmed that BMP-2 could induce chondrocytes hypertrophic in
FDC model.
Conclusions: We have developed an explants culture models that include
all the different layers of the articular cartilage and were able to induce
hypertrophy by stimulating with BMP-2. We could detect the gene expres-
sion of markers at different subpopulations of chondrocytes in the ex vivo
culture model. We speculate that this model could be used as an important
ex vivo model for simulating cartilage degenerative diseases and thereby
for investigating the effect of different drug candidates.
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GLUCOCORTICOIDS ATTENUATE BONE TURNOVER, BUT DO NOT APPEAR
TO AFFECT CHONDROCYTESIN VITRO
K. Henriksen, K.V. Andreassen, S.H. Madsen, M.A. Karsdal, A.-C. Bay-Jensen
Nordic BioSci. A/S, Herlev, Denmark
Purpose: Glucocorticoids are known to attenuate bone formation in vivo
leading to decreased bone volume and increased risk of fractures, whereas
effects on the joint tissue are not known. This study aimed at characterizing
the effect of glucocorticoids on osteoclasts and osteoblasts, as well as the
closely related chondrocytes.
Methods: We used CD14+ monocytes cultured in the presence of M-CSF
and RANKL to investigate the effect of glucocorticoids on different osteo-
clastic parameters. We measured TRACP activity and Calcium release as
indices of osteoclast number and activity. 2T3 preosteoblastic cells we used
to characterize the effects of glucocorticoids on bone formation, either
in the presence or absence of BMP-2. Alizarin Red was used to measure
nodule formation, ALP activity as an indicator of osteoblastogenesis. Bovine
full depth cartilage explants were cultured with or without TNF-a, OSM and
IGF-1 to characterize the effects of glucocorticoids on cartilage turnover.
Collagen type II degradation was measured by CIIMB, and aggrecan degra-
dation by 373-G1. Safranin O staining was used to investigate proteoglycan
content in sections of the cultured explants. In all assays Alamar Blue was
used as an indicator of viability.
Results: DEX and PRED dose-dependently inhibited osteoclastogenesis by
promoting cell death. For mature osteoclasts, low doses of GLUC induced
bone resorption short term, whereas high doses and continued exposure
led to osteoclast death. In osteoblasts glucocorticoids induced cell death in
the non-stimulated cells. For BMP-2 stimulated cells; we found that GLUCs
augmented nodule formation, while still reducing cell viability. In cartilage
we found that GLUCs were unable to alter cartilage turnover, although at
high concentrations a minor reduction in safranin O staining intensity was
observed.
Conclusions: In summary, using highly robust models of bone and car-
tilage turnover, we have shown that the effects of glucocorticoids on
bone depend very much in the cell targeted, i.e. activated osteoblasts are
further activated by GLUC, whereas non-activated cells undergo cell death.
In cartilage no apparent effects were observed, indicating that cartilage
may not possess glucocorticoid receptors, or that these are not active. We
believe that these model systems are highly relevant for the continued
development of glucocorticoid analogues without the detrimental effect on
bone
